(Total Views: 39)
Posted On: 06/24/2025 4:22:15 PM
Post# of 192
NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Taps IBN to Lead Corporate Communications Amid Drug Advancements and Subsidiary Launch
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to manage its corporate communications strategy. NRx is advancing two FDA-designated therapies—NRX-100 and NRX-101—with an NDA underway for NRX-100 and additional regulatory filings in progress. The company also launched HOPE Therapeutics, a subsidiary focused on building a national psychiatric care network, with plans for a public spin-out. IBN will leverage its extensive media portfolio to expand investor awareness and outreach.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to manage its corporate communications strategy. NRx is advancing two FDA-designated therapies—NRX-100 and NRX-101—with an NDA underway for NRX-100 and additional regulatory filings in progress. The company also launched HOPE Therapeutics, a subsidiary focused on building a national psychiatric care network, with plans for a public spin-out. IBN will leverage its extensive media portfolio to expand investor awareness and outreach.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
